New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
05:34 EDTSNYSanofi, Transgene launch construction phase of new bioproduction platform
Sanofi and Transgene SA announced that they have launched the construction phase of the manufacturing platform dedicated to the production of viral vectors, such as Transgene’s MUC1 targeted cancer immunotherapy, TG4010. In March 2013, the companies announced a long-term collaboration agreement to build the unit, which is to be constructed on the Genzyme Polyclonals site in Lyon, an important French biopharmaceutical cluster. The companies together will invest approximately EUR 10M in the production unit over an expected two-year timeframe, of which Transgene's share will be approximately EUR 5M. This dedicated platform will be Sanofi’s exclusive property and will enable to produce a new breakthrough class of APIs.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
12:36 EDTSNYOn The Fly: Top stock stories at midday
Subscribe for More Information
08:01 EDTSNYRetrophin agrees to sell Pediatric PRV to Sanofi
Retrophin (RTRX) announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (SNY). Retrophin received the Pediatric PRV when Cholbam was approved by the U.S. FDA for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders. Upon closing of the transaction, Retrophin will receive a payment of $150M, followed by two equal installments of $47.5M in 2016 and 2017. The company will receive a total consideration of $245M in cash from Sanofi in exchange for the Pediatric PRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
May 26, 2015
08:14 EDTSNYBoston Biotech Conferences to hold a conference
Subscribe for More Information
08:01 EDTSNYSanofi's Genzyme to present Aubagio, Lemtrada data at CMSC
Subscribe for More Information
May 22, 2015
10:52 EDTSNYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
14:48 EDTSNYRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
05:15 EDTSNYRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 19, 2015
06:55 EDTSNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use